TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Digestive System Department
Division of General Internal Medicine
更新時間：2023-09-19
高嘉宏Kao, Jia-Horng
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
53Publications
11
Tseng TC, Liu CJ, Yang WT, Hsu CY, Hong CM, Su TH, Tsai CH, Chen CL, Yang HC, Liu CH, Chen HH, Chen PJ, Kao JH. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021 Apr;53(8):908-918. doi: 10.1111/apt.16266. Epub 2021 Jan 19. PMID: 33465271.
12
Wang CC, Tseng KC, Tzeng IS, Kao JH. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc. 2021 Mar;120(3):965-973. doi: 10.1016/j.jfma.2020.10.015. Epub 2020 Oct 29. PMID: 33129621.
13
Yu ML, Tsai WL, Chu CJ, Kao JH. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. Kaohsiung J Med Sci. 2021 Mar;37(3):245-252. doi: 10.1002/kjm2.12317. Epub 2020 Oct 22. PMID: 33089964.
14
Huang SC, Liao SH, Su TH, Jeng YM, Kao JH. Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. Hepatol Int. 2021 Apr;15(2):472-481. doi: 10.1007/s12072-021-10146-1. Epub 2021 Feb 5. PMID: 33544314.
15
Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int. 2021 Apr;15(2):405-412. doi: 10.1007/s12072-021-10147-0. Epub 2021 Feb 4. PMID: 33539004.
16
Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol. 2021 Mar;36(3):569-580. doi: 10.1111/jgh.15415. PMID: 33709606.
17
Tseng TC, Liu CJ, Chang CT, Su TH, Yang WT, Tsai CH, Chen CL, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J Hepatol. 2020 Jun;72(6):1105-1111. doi: 10.1016/j.jhep.2020.01.012. Epub 2020 Mar 12. PMID: 32006586.
18
Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020 May;72(5):839-846. doi: 10.1016/j.jhep.2019.11.014. Epub 2019 Nov 29. PMID: 31790766.
19
Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat. 2020 Jun;27(6):568-575. doi: 10.1111/jvh.13265. Epub 2020 Feb 6. PMID: 31981264.
20
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Feb 26;33(2):e00046-19. doi: 10.1128/CMR.00046-19. PMID: 32102898; PMCID: PMC7048015.
